Clinical Trial Update: Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

View source ↗

Summary

This document provides an update on a completed clinical trial evaluating adjuvant dabrafenib and trametinib in patients with completely resected high-risk stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Status: COMPLETED